TCCSUP Xenograft Model Service for Bladder Cancer

The TCCSUP xenograft model offers a robust preclinical platform for evaluating therapeutic strategies against aggressive bladder cancer. At Alfa Cytology, we specialize in constructing and validating high-fidelity TCCSUP xenograft models to accelerate your oncology drug development pipeline, providing reproducible tumor growth kinetics and comprehensive pharmacodynamic endpoints tailored to your research objectives.

Overview of TCCSUP Xenograft Model for Bladder Cancer

The TCCSUP cell line was established in 1974 from a Grade IV anaplastic transitional cell carcinoma (TCC) located in the neck of the urinary bladder, derived from a 67-year-old female patient of European descent. Histologically, TCCSUP represents high-grade, poorly differentiated urothelial carcinoma with aggressive malignant characteristics, including rapid proliferation, high invasiveness, and resistance to conventional chemotherapy. The cell line exhibits an abnormal hypotetraploid karyotype with distinct marker chromosomes and displays both epithelial-like and fibroblast-like morphological features, reflecting the inherent heterogeneity of advanced bladder tumors. Molecular profiling has identified key alterations in PI3K/AKT and MAPK signaling pathways, including a documented PIK3CA E545K mutation, making TCCSUP one of the most comprehensively characterized bladder cancer cell lines across multiple genomic and proteomic panels.

In xenograft applications, TCCSUP cells are typically implanted into immunodeficient mouse strains such as BALB/c nude or NOD-SCID mice to establish subcutaneous or orthotopic tumor models. While TCCSUP demonstrates robust in vitro growth, its in vivo tumorigenic potential varies depending on implantation site and host strain; subcutaneous models generally exhibit reliable tumor take rates with measurable growth kinetics, whereas orthotopic bladder wall implantation may require mucosal pretreatment to enhance engraftment. The TCCSUP xenograft model serves as a critical tool for studying tumor-stroma interactions, evaluating targeted agents against PI3K pathway alterations, and investigating mechanisms of metastasis and therapeutic resistance in high-grade bladder carcinoma.

Figure 1. miR-152-3p inhibited the invasion and migration of bladder cancer cells. (Li, Shouchun, et al., 2023)

Cell Line Information: TCCSUP

The following table summarizes the essential characteristics and technical specifications of the TCCSUP cell line for xenograft model development:

Our Services

Alfa Cytology leverages the TCCSUP cell line's well-documented molecular profile and aggressive tumorigenic phenotype to deliver validated xenograft models with consistent tumor take rates and predictable growth kinetics. Our preclinical services encompass model establishment, in-life monitoring, tumor volume tracking, and comprehensive endpoint analysis---including histopathology, biomarker assessment, and pharmacokinetic/pharmacodynamic correlation---to support your bladder cancer therapeutic development from lead optimization through IND-enabling studies.

Workflow of TCCSUP Xenograft Model Construction

The construction of a TCCSUP xenograft model follows a standardized, quality-controlled workflow designed to ensure reproducible tumor growth and reliable pharmacological readouts. Each stage is executed under stringent protocols with documented quality checks:

1. Cell Line Authentication and Expansion: TCCSUP cells are retrieved from authenticated stocks (ATCC HTB-5 or equivalent) and expanded under standardized culture conditions. Mycoplasma testing and STR profiling are performed to confirm identity prior to inoculation.
2. Host Strain Selection and Preparation: Immunodeficient mice (typically BALB/c nude or NOD-SCID, 6--8 weeks old) are acclimatized under specific-pathogen-free (SPF) conditions. Animals are randomized by body weight and baseline health parameters are recorded.
3. Tumor Cell Inoculation: Exponentially growing TCCSUP cells are harvested, washed, and resuspended in serum-free medium mixed with Matrigel (1:1 ratio) to enhance engraftment. For subcutaneous models, 1x10^6 to 5x10^6 cells are injected into the flank; for orthotopic models, cells are instilled into the bladder lumen following mucosal pretreatment.
4. Tumor Monitoring and Randomization: Tumor development is monitored by palpation and/or caliper measurement twice weekly. Upon reaching a mean tumor volume of 100--150 mm^3, animals are randomized into treatment cohorts to minimize inter-group variability.
5. Therapeutic Intervention and Endpoint Collection: Test compounds are administered according to the study design (dosing route, frequency, and duration). Tumor dimensions and body weights are recorded throughout the study. At termination, tumors are excised, weighed, and processed for histology, biomarker analysis, and molecular profiling.

Figure 2. TCCSUP xenograft model construction workflow.

Case Study-TCCSUP Xenograft Model Development

In a representative preclinical engagement, Alfa Cytology established subcutaneous TCCSUP xenografts in immunodeficient mice to evaluate a novel PI3K pathway inhibitor. The model demonstrated consistent tumor take rates exceeding 85% with median time-to-palpability of 12--14 days. Tumor growth kinetics showed exponential expansion through Day 28, with vehicle-control tumors reaching volumes of 800--1,200 mm^3. Treatment arms exhibited dose-dependent tumor growth inhibition, with the highest dose cohort achieving statistically significant reduction in tumor burden compared to control. Comprehensive endpoint analysis included H&E staining, Ki67 proliferation index assessment, and downstream pathway marker evaluation (p-AKT, p-S6). Detailed efficacy data, pharmacokinetic profiles, and biomarker correlations are available upon request under confidentiality agreements.

Why Choose Alfa Cytology?

Alfa Cytology delivers differentiated preclinical oncology services through rigorous scientific execution and client-centric study design. Our TCCSUP xenograft model service offers distinct advantages for bladder cancer drug development programs:

• Authenticated cell lines with verified STR profiles and documented passage history ensure genetic fidelity across studies.
• Customizable model configurations including subcutaneous, orthotopic, and metastatic dissemination formats to match your scientific objectives.
• Integrated pharmacodynamic endpoints encompassing tumor histopathology, immunohistochemistry, and molecular biomarker quantification.
• Real-time tumor monitoring with electronic data capture and statistical analysis support for robust study reporting.
• Dedicated project management with flexible scheduling and rapid study initiation to accelerate your development timeline.

Contact Us

Ready to advance your bladder cancer therapeutic program with a validated TCCSUP xenograft model? Contact us today to discuss your study requirements, receive a customized proposal, or schedule a consultation with our preclinical oncology team. We look forward to partnering with you to drive your research from concept to clinic. Please reach out to us today via our inquiry form or email to learn more about our TCCSUP Xenograft Model services.

For research use only. Not intended for any clinical use.